# US 8,278,303 B2 · Phosphine transition metal complex, process for producing same, and anticancer agent

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,303 B2
- Document ID: US8278303B2
- Status: Granted
- Kind: B2
- Application number: 12/302,517
- Filed: 2007-05-31
- Published: 2010-02-25
- Granted: 2012-10-02
- Earliest claimed: 2006-06-01
- Assignees: Nippon Chemical Industrial Co., Ltd.
- Inventors: Hiroaki Kodama; Keisuke Ohto; Nobuhiko Oohara; Kazuhiro Nakatsui; Yoshirou Kaneda
- Web page: https://patentgrep.com/patent/US8278303B2

## CPC

- C07F 9/650994: {condensed with carbocyclic rings or carbocyclic ring systems}
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 35/04: specific for metastasis
- C07F 9/650952: {having the nitrogen atoms in the positions 1 and 4}
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

An anticancer agent having a novel chemical structure and high anticancer activity is provided. A phosphine transition metal complex of general formula (1) and an anticancer agent containing the complex are disclosed. R1 and R2, which may be the same or different, each represent a group having 1 to 10 carbon atoms selected from a straight-chain or branched alkyl group, a cycloalkyl group, a substituted cycloalkyl group, an adamantyl group, a phenyl group, and a substituted phenyl group; R3 and R4, which may be the same or different, each represent a hydrogen atom, a straight-chain alkyl group having 1 to 6 carbon atoms or branched alkyl group having 1 to 6 carbon atoms; or R3 and R4 are taken together to form a saturated or unsaturated ring which may have a substituted group; M represents a transition metal atom selected from the group consisting of gold, copper, and silver; and X− represents an anion.

## Claims

### Claim 1

A phosphine transition metal complex represented by formula (1):
wherein
R1 and R2, which are the same or different, each represent a group having 1 to 10 carbon atoms selected from a straight-chain or branched alkyl group, a cycloalkyl group, a substituted cycloalkyl group, an adamantyl group, a phenyl group, and a substituted phenyl group, wherein a substituent of the substituted cycloalkyl group or the substituted phenyl group as R1 or R2 is selected from the group consisting of alkyl, nitro, amino, hydroxy, fluoro, chloro, bromo or iodo;
R3 and R4 taken together represent a benzene ring with or without a substituted group, wherein the substituted group is selected from the group consisting of a straight-chain alkyl group having 1 to 5 carbon atoms, a branched alkyl group having 1 to 5 carbon atoms, a nitro group, an amino group, a hydroxy group, a fluoro group, a chloro group, a bromo group, and an iodo group;
M is gold; and
X− represents an anion, wherein the anion is selected from the group consisting of chloride ion, bromide ion, iodide ion, tetrafluoroborate ion, hexafluorophosphate ion, and perchlorate ion.

### Claim 2 (depends on 1)

The phosphine transition metal complex according to claim 1, wherein R1 is a t-butyl group or an adamantyl group, and R2 is a methyl group.

### Claim 3

A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a phosphine transition metal complex represented by formula (1):
wherein
R1 and R2, which are the same or different, each represent a group having 1 to 10 carbon atoms selected from a straight-chain or branched alkyl group, a cycloalkyl group, a substituted cycloalkyl group, an adamantyl group, a phenyl group, and a substituted phenyl group, wherein a substituent of the substituted cycloalkyl group or the substituted phenyl group as R1 or R2 is selected from the group consisting of alkyl, nitro, amino, hydroxyl, fluoro, chloro, bromo or iodo;
R3 and R4 taken together represent a benzene ring with or without a substituted group, wherein the substituted group is selected from the group consisting of a straight-chain alkyl group having 1 to 5 carbon atoms, a branched alkyl group having 1 to 5 carbon atoms, a nitro group, an amino group, a hydroxy group, a fluoro group, a chloro group, a bromo group, and an iodo group;
M is gold; and
X− represents an anion, wherein the anion is selected from the group consisting of chloride ion, bromide ion, iodide ion, tetrafluoroborate ion, hexafluorophosphate ion, and perchlorate ion.

### Claim 4 (depends on 3)

The pharmaceutical composition comprising a pharmaceutically acceptable carrier and a phosphine transition metal complex according to claim 3, wherein R1 is a t-butyl group or an adamantyl group, and R2 is a methyl group.

### Claim 5

A phosphine transition metal complex, which is represented by formula (2):
wherein
R1 and R2, which are the same or different, each represent a group having 1 to 10 carbon atoms selected from a straight-chain or branched alkyl group, a cycloalkyl group, a substituted cycloalkyl group, an adamantyl group, a phenyl group, and a substituted phenyl group, wherein a substituent of the substituted cycloalkyl group or the substituted phenyl group as R1 or R2 is selected from the group consisting of alkyl, nitro, amino, hydroxyl, fluoro, chloro, bromo or iodo;
R5 represents a monovalent substituent; n represents an integer of 0, 1, 2, 3 or 4, wherein the monovalent substituent is selected from the group consisting of a straight-chain alkyl group having 1 to 5 carbon atoms, a branched alkyl group having 1 to 5 carbon atoms, a nitro group, an amino group, a hydroxy group, a fluoro group, a chloro group, a bromo group, or an iodo group;
M is gold; and
X− represents an anion, wherein the anion is selected from the group consisting of chloride ion, bromide ion, iodide ion, tetrafluoroborate ion, hexafluorophosphate ion, and perchlorate ion.

### Claim 6 (depends on 5)

The phosphine transition metal complex according to claim 5, wherein R1 is a t-butyl group or an adamantyl group, and R2 is a methyl group.
